about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Eli Lil­ly high­lights key R&D cat­a­lysts for 2018; Ver­nalis and Dai­ichi Sankyo work to­geth­er on can­cer tar­gets

8 years ago
News Briefing

Dai­ichi ditch­es Nek­tar fol­low­ing can­cer drug flop

8 years ago
R&D

Yer­voy in­ven­tor's on­col­o­gy start­up Pi­o­nyr gets $62M for tu­mor-fight­ing tech

8 years ago
Financing

Ex-Dez­i­ma CEO co-founds NASH start­up, fly­ing in­to Phase IIB with €25 mil­lion

8 years ago
Startups

In lat­est blow to Eli Lil­ly, Sanofi wins FDA OK for Hu­ma­log me-too

8 years ago
Pharma

M&A slows to a trick­le in 2017, but Big Phar­ma could be on deck for mega deals

8 years ago
Deals

Ac­tivists threat­en to push for a sale of Alex­ion if ex­ecs can't jack up stock price

8 years ago
Pharma

Daniel Swish­er leaves an ail­ing Sune­sis and swoops in to lead Jazz Phar­ma­ceu­ti­cals

8 years ago
Peer Review

Canada's AmorChem launch­es $44.2M life sci­ence fund; Neon adds $36M, Mer­ck part­ner­ship in neoanti­gen dri­ve; CRISPR ...

8 years ago
News Briefing

Tak­ing on gam­ma delta T cells, blue­bird pays $16M for TC Bio­Phar­m's tu­mor in­vad­ing tech plat­form

8 years ago
Pharma

Rich Hey­man's Metacrine grabs a $22M round in search of a su­pe­ri­or NASH drug

8 years ago
Financing
Startups

Madri­gal's stock soars on promis­ing PhII da­ta in NASH, but ques­tions linger

8 years ago
R&D

Clin­i­cal tri­al trans­paren­cy im­proves at (some) bio­phar­mas as J&J, Sanofi lead a pack trailed by Valeant and Al­ler­gan

8 years ago
Pharma

Cel­lec­tis re­cruits ex-Servi­er re­search chief De­pil; Are­na inks $224M deal on new drugs; JLABS heads to Shang­hai; ...

8 years ago
News Briefing

Watch out Al­ler­gan: Re­vance’s wrin­kle-re­duc­er beats Botox in PhI­II tri­als

8 years ago
R&D

Ven­ter quick­ly grabs the reins back at Hu­man Longevi­ty; Pe­ter Thiel backs up­start ChemomAb

8 years ago
News Briefing

Atox Bio clos­es $30M round as it speeds through late-stage tri­als

8 years ago
Financing

In­di­v­ior tight­ens grip on opi­oid ad­dic­tion mar­ket with Sublo­cade's new FDA ap­proval

8 years ago
Pharma

Sen­a­tors grill Alex Azar on drug prices; Mor­phoSys sells rights to Darza­lex ri­val in $120M deal; Se­r­i­al deal­mak­er ...

8 years ago
News Briefing

An­ti-ag­ing start­up ResTOR­bio gets $40M to fu­el Phase IIb study

8 years ago
Financing

Am­gen pulls ahead in sprint to­wards CGRP ap­proval with promis­ing PhI­II mi­graine da­ta

8 years ago
R&D

New back­ers Sofinno­va and Scopia bring Y-mAb's round to $80M for an­ti-can­cer drugs

8 years ago
Financing

Fra­zier backs MavuPhar­ma’s $20M round, brings in heavy­weight ex­ecs to lead

8 years ago
Financing
Startups

RA backs Mede­or’s $57M round as re­searchers fast for­ward to PhI­II

8 years ago
Financing
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times